Migraine sufferers anxiously await the day when a pill will suddenly make the pain and other symptoms cease. Unfortunately, even the latest in medication doesn’t seem to promise those results. One new drug called galcanezumab was tested on chronic migraines sufferers. You might be surprised to learn what the pharmaceutical industry considers a successful study.
The test consisted of chronic migraine patients who averaged 19.7 episodes per month. Patients took the drug in two doses, with the lower dose performing the better of the two. This dose, 120 mg, resulted in 4.8 fewer episodes for patients, decreasing the average to 14.9 days per month. With the number dropped to below 15 days per month, a person is no longer having chronic migraines.
As a result, this medication could be the next treatment for chronic migraines and analysts expect sales to reach close to half a billion US dollars by 2022. Here are two problems with the results.
Upper cervical chiropractic offers a far less expensive way to approach chronic migraines. A misalignment of the atlas (C1) or axis (C2) is often an underlying cause of this neurological condition. If such a misalignment is restricting blood and cerebrospinal fluid flow or affecting brainstem function, migraines can result. A gentle and precise correction has helped many to find relief. Some see fewer and less severe episodes, while others may attain total relief. To learn more about this natural approach to get relief, contact an upper cervical practice near you.
The content and materials provided in this web site are for informational and educational purposes only and are not intended to supplement or comprise a medical diagnosis or other professional opinion, or to be used in lieu of a consultation with a physician or competent health care professional for medical diagnosis and/or treatment. All content and materials including research papers, case studies and testimonials summarizing patients' responses to care are intended for educational purposes only and do not imply a guarantee of benefit. Individual results may vary, depending upon several factors including age of the patient, severity of the condition, severity of the spinal injury, and duration of time the condition has been present.